Clinical Trials Logo

Obsessive-Compulsive Disorder clinical trials

View clinical trials related to Obsessive-Compulsive Disorder.

Filter by:
  • Enrolling by invitation  
  • Page 1 ·  Next »

NCT ID: NCT05855902 Enrolling by invitation - Clinical trials for Obsessive-Compulsive Disorder

Art Therapy in an Intensive OCD Program

Start date: March 23, 2023
Phase:
Study type: Observational

The Thompson Centre Intensive Treatment program for individuals with severe Obsessive-Compulsive Disorder was launched in 2017. The program is focused on the principles and use of Exposure and Response Prevention Therapy (ERP) and Cognitive Behavioural Therapy (CBT) in its work with clients, however it also integrates other treatment approaches in its structure, including Dialectical Behavior Therapy, Mindfulness, Acceptance and Commitment Therapy, and Art Therapy. Clients are expected to participate in Art Therapy group in the same way they are expected to participate in all other groups in the program schedule. Though clients comment informally on the benefits of Art Therapy as experienced in the program, study is needed to better understand and appreciate the role Art Therapy can play in helping clients with OCD to manage and where possible, ameliorate, the burden of their symptoms. Although Art Therapy has been researched to some degree, in particular its role in alleviating distress associated with various health and mental health conditions, to date there has been no systematic investigation addressing or supporting patients'/clients' perception of the value of Art Therapy by people who live with Obsessive Compulsive Disorder (OCD). In this study, the investigators are proposing to use information from client surveys regarding their experiences in an Art Therapy group within an intensive OCD treatment program, regarding their experience and opinions about the benefits of Art Therapy within a structured, intensive program for individuals who live with severe OCD. Therefore, this proposed study would be an entirely new contribution both to the fields of Art Therapy and OCD. The hypothesis of the study is that individuals with severe Obsessive-Compulsive Disorder participating in an intensive CBT/ERP treatment program will report benefits specific to their experience in Art Therapy sessions within the program.

NCT ID: NCT05659082 Enrolling by invitation - Clinical trials for Obsessive-Compulsive Disorder

Ventral Capsulotomy for Intractable OCD

Start date: June 21, 2022
Phase: Phase 3
Study type: Interventional

Obsessive-compulsive disorder impacts 1-2 percent of the population. Unfortunately, about fifteen percent of patients fail to benefit from existing therapies. A small number of OCD patients, who have a disabling illness that does not improve after conventional treatments, have neurosurgery as a last resort. One procedure, capsulotomy, involves making pairs of lesions in an anatomically-defined part of the anterior limb of the internal capsule, a structure containing nerve fiber bundles connecting the thalamus, in the center of the brain, to the prefrontal cortex, the most anterior and outermost brain region. The investigators will examine how the therapeutic effects of capsulotomy relate to changes in the structure of these brain pathways with structural (diffusion tensor imaging, DTI) and functional (resting-state and task-based) connectivity metrics. The investigators will also utilize experimental cognitive tasks that are sensitive to the circuitry impacted by this procedure.

NCT ID: NCT05565352 Enrolling by invitation - Clinical trials for Major Depressive Disorder

Observation of Ketamine Treatment Safety and Tolerability in Adult Psychiatry Clinic Medical University of Gdańsk Inpatients

KetGD
Start date: September 1, 2022
Phase:
Study type: Observational

Adult Psychiatry Clinic Medical University of Gdańsk (MUG) is a healthcare facility that provides ketamine treatment to adult patients suffering from mental health conditions. The Clinic especially treats individuals suffering from treatment-resistant disorders, like - mood disorders, anxiety disorders, obsessive-compulsive and related disorders, trauma and stressor-related disorders, somatic symptom and related disorders, and dissociative disorders. Herein, this naturalistic observation aims to look at the safety and tolerability of ketamine treatment to further develop the understanding of ketamine in the use of psychiatry.

NCT ID: NCT05254015 Enrolling by invitation - Clinical trials for Obsessive-Compulsive Disorder

Cognitive Rehabilitation and Exposure Therapy for Geriatric Hoarding

CREST
Start date: November 21, 2022
Phase: N/A
Study type: Interventional

Hoarding disorder (HD) is a chronic, progressive, and debilitating psychiatric condition that leads to devastating personal and public consequences, particularly for older adults. This confirmatory efficacy trial will advance our knowledge of the mechanisms of action in the treatment of HD as well as reduce symptom severity, disability, and community consequences.

NCT ID: NCT04775875 Enrolling by invitation - Clinical trials for Obsessive-Compulsive Disorder

The Use of Transcranial Ultrasound Treatment of Obsessive-Compulsive Disorder

Start date: December 1, 2020
Phase: N/A
Study type: Interventional

The primary objective of this study is to determine the safety and efficacy of ultrasound as a treatment for Obsessive Compulsive disorder.

NCT ID: NCT04708834 Enrolling by invitation - Clinical trials for Obsessive Compulsive Disorder

Long-term Safety Study of Adjunctive Troriluzole in Subjects With Obsessive Compulsive Disorder

Start date: March 30, 2021
Phase: Phase 3
Study type: Interventional

The purpose of the study is to evaluate the long term safety and tolerability of troriluzole as adjunctive therapy in subjects with obsessive compulsive disorder (OCD).

NCT ID: NCT04323566 Enrolling by invitation - Schizophrenia Clinical Trials

Rituximab Treatment for Psychosis and/or Obsessive Compulsive Disorder With Probable Immune System Involvement

Ra-P-OCD
Start date: May 1, 2022
Phase: Phase 2
Study type: Interventional

The primary objective for this study is to evaluate whether Rituximab as compared to placebo is a clinically effective treatment for a subgroup of patients suffering from psychosis and/or obsessive-compulsive disorder (OCD) or -behavior (OCB) where there is an indication of immune system involvement. The secondary objectives of this study are 1. To assess whether Rituximab treatment (with the doses and timing described below) as compared to placebo is associated with amelioration in psychiatric symptomatology 2. To assess whether Rituximab treatment as compared to placebo is associated with improvement in executive functions 3. To assess whether Rituximab treatment as compared to placebo is associated with amelioration in neurological symptoms 4. To evaluate the longevity of psychiatric, neurological and executive improvements associated with Rituximab treatment for up to 16 months after the first infusion (i.e. 12 months after the last infusion) 5. To evaluate whether Rituximab treatment as described is safe for these patients. The exploratory objectives of this study are 1. To assess changes in blood and cerebrospinal fluid (CSF) markers for immune activity associated with Rituximab treatment compared to placebo 2. To assess statistical associations between biological markers in blood or CSF and clinical response 3. To describe changes in somatic symptoms associated with treatment with Rituximab vs placebo for patients with initial symptoms in the questionnaires 4. To describe changes on MR and EEG associated with treatment with Rituximab vs placebo for patients with initial pathology in these examination 5. To study immune mechanisms coupled with psychiatric symptoms, possibly identifying novel biomarkers with potential for subtyping encephalopathies with immune engagement, using biobank cells, blood and CSF samples collected from the participants.

NCT ID: NCT04209296 Enrolling by invitation - Clinical trials for Major Depressive Disorder

Chart Review of Patients Undergoing Ketamine Infusions

Start date: December 3, 2019
Phase:
Study type: Observational

The Canadian Rapid Treatment Center of Excellence (CRTCE) is a healthcare facility principally focused on providing best practices of intravenous ketamine treatment to adult patients suffering from mental health conditions. The center focuses specifically on treating individuals suffering from major depression disorder, bipolar disorder, post-traumatic stress disorder and obsessive compulsive disorder as their primary diagnosis. Herein, this retrospective analysis aims to look at past data in order to further develop our understanding of ketamine in the use of psychiatry.

NCT ID: NCT03324906 Enrolling by invitation - Obesity Clinical Trials

Effects of Transcranial Direct Current Stimulation (tDCS) on Individuals With Prader-Willi Syndrome

Start date: May 8, 2017
Phase: N/A
Study type: Interventional

Prader-Willi Syndrome (PWS) is a multisystemic genetic disease characterized by hypotonia, mental retardation, hyperphagia, and uncontrollable hunger due to hypothalamic dysfunction, caused by dysregulation of genes located in chromosome 15q11-q13. The goal of this study is to evaluate the effects of Transcranial Direct Current Stimulation (tDCS) on hyperphagia and behavior in PWS. Forty children and adolescents (11-24 years) with clinical and cytogenetic-molecular diagnosis of Prader-Willi syndrome will be assessed before and after 10 tDCS session with: Food Craving Questionnaire (FCQ), Aberrant Behavior Checklist (ABC), Dykens hyperphagia questionnaire. Caregivers self-reported the participant's behaviors at home and, lately, they will be categorized and quantified. tDCS will be applied for 20 minutes with electrodes of 25cm2 wrapped in cotton material soaked in saline solution. The anode at the left dorsolateral prefrontal cortex (F3) and the cathode at the contralateral area (F4). Children from 11-12 years will receive a current of 1mA; above 13 years, 2mA.

NCT ID: NCT02320266 Enrolling by invitation - Parkinson's Disease Clinical Trials

Sensory Gating Measured With Microelectrode Recording (MER) During Deep Brain Stimulation (DBS) Surgery

Start date: December 2014
Phase:
Study type: Observational

Deep brain stimulation (DBS) is an FDA approved, and widely used method for treating the motor symptoms of Parkinson's disease (PD), Essential Tremor (ET), Dystonia and Obsessive Compulsive disorder (OCD). Over 100,000 patients worldwide have now been implanted with DBS devices. Current approved methods to locate the DBS target regions in the brain use a combination of stereotactic imaging techniques and measurements of the electrical activity of brain cells. As part of the standard clinical technique, electrical data are collected from individual nerve cells. The target brain region emits unique electrical signals. At certain brain locations, during DBS surgery, additional electrical data that are generated in response to sound will be collected. Regions of the brain that have a decreased response to repeated sound (auditory gating) may be important DBS targets for improving thinking. The aims are (i) during DBS surgery, in addition to EEG, use microelectrodes in the brain to find brain regions, along the normal path to the DBS target, where auditory gating occurs and then (ii) determine if stimulation of the identified region(s) alters auditory gating measured by EEG. Also an additional aim (iii) is to measure electrical activity at the scalp with EEG to characterize auditory gating in patients before and after DBS surgery and also a healthy control population.